Eli Lilly's LY4005130 Trial for Severe Alopecia Areata Underway
Eli Lilly is conducting a trial to evaluate the efficacy and safety of LY4005130 in adults with severe alopecia areata.
Asset / Drug
Drug and asset intelligence for Severe Alopecia with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.